Overview
- 7 inspections across 6 sites are on record.
- 11 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-02-01.
At a glance
Inspections
7
Sites
6
Observations
11
Career since
Dec 2015
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Eisai Manufacturing Ltd | 1 Feb 2019 | Human Drugs | View 483 → |
| AstraZeneca Pharmaceuticals LP | 11 Oct 2018 | Human Drugs | |
| Eisai, Inc. | 16 Feb 2018 | Human Drugs | View 483 → |
| Rho, Inc. | 30 Jun 2017 | Human Drugs | View 483 → |
| Ironshore Pharmaceuticals & Development, Inc. | 7 Mar 2017 | Human Drugs |
Sites inspected
Eisai Manufacturing LtdHatfield, United Kingdom1 insp.
AstraZeneca Pharmaceuticals LPGaithersburg, United States1 insp.
Eisai, Inc.Nutley, United States1 insp.
Rho, Inc.Chapel Hill, United States1 insp.
Ironshore Pharmaceuticals & Development, Inc.Grand Cayman, Cayman Islands1 insp.
Co-investigators
Investigators who share inspections with this person.
Michael Serrano3 shared
Lauren C Iacono-Connors2 shared
Peter R Lenahan2 shared
Nina Yang2 shared
Craig A Garmendia1 shared
Robin R Waller1 shared
Bei Yu1 shared
David L Chon1 shared
Melanie N Daniels1 shared
Jenn W Sellers1 shared
Full investigator report
Get the verbatim findings behind Jean M Mulinde's 11 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site